Compare KB Financial Group, Inc. (KB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Viatris Inc — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: KB Financial Group, Inc. is far larger — about 2.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Viatris Inc for 57 Days on average.
| KB | VTRS | |
|---|---|---|
Market Cap | $42.62B | $20.03B |
Volume | 164,291 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $132.88 | $18.27 |
52-Week Low | $77.50 | $9.74 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $215.53T | $32.15B |
Dividend Yield | 2.71% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $122.04, down 2.16% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.68, P/B of 0.94, and consistent earnings beats in recent quarters. Revenue grew from $17.77T in 2022 to $21.23T in 2025, with net income rising to $5.83T. Operating cash flow improved significantly to $4.23T in 2025, while analyst consensus shows 33% buy ratings amid positive momentum coverage.
KB presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term consolidation. Key risks include market volatility and execution challenges in non-banking expansion. The stock's current price near support levels and strong institutional interest support a cautiously optimistic outlook for patient investors.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
